GSTT1 and GSTM1 deletions, NQO1 C609T polymorphism and risk of chronic myelogenous leukemia in Japanese

Asian Pacific Journal of Cancer Prevention

Volumn 6, Issue 3, 2005, Pages 251-255

  Hishida, Asahi ^a   Terakura, Seitaro ^a   Emi, Nobuhiko ^a   Yamamoto, Kazuhito ^a   Murata, Makoto ^a   Nishio, Kazuko ^a   Sekido, Yoshitaka ^b   Niwa, Toshimitsu ^b   Hamajima, Nobuyuki ^a   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC MYELOID LEUKEMIA; FEMALE; GENE DELETION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; JAPAN; MALE; MIDDLE AGED; RISK; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; JAPAN; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS; SEQUENCE DELETION;

EID: 32944467880     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Asher G, Lotem J, Kama R, Sachs L, Shaul Y (2002). NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA, 99, 3099-104.
2. Chen H, Lum A, Seifried A, Wilkens LR, Le Marchand L (1999). Association of the NAD(P)H:quinone oxidoreductase 609 C_T polymorphism with a decreased lung cancer risk. Cancer Res, 59, 3045-8.
3. Garte S, Gaspari L, Alexandrie AK, et al (2001). Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomark Prev, 10, 1239-48.
4. Hamajima N, Matsuo K, Iwata H, et al (2002a). NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol, 7, 103-8.
5. Hishida A, Matsuo K, Hamajima N, et al (2003a). Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Haematologica, 88, 159-66.
6. Hishida A, Matsuo K, Hamajima N, et al (2003b). Polymorphism in the hMSH2 gene (gIVS 12-6T→C) and risk of non- Hodgkin lymphoma in a Japanese population. Cancer Genet Cytogenet, 147, 71-4.
7. Hishida A, Matsuo K, Tajima K, et al (2004). Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at Exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's Lymphoma in Japanese. Leuk Lymphoma, 45, 957-64.
8. Houlston RS (1999). Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 8, 675-82.
9. Kawase H, Hamajima N, Tamakoshi A, et al (2003). Triplex polymerase chain reaction with confronting two-pair primers (PCR-CTPP) for NQO1 C609T, GSTM1, and GSTT1 polymorphisms: the most convenient genotyping method. Asian Pac J Cancer Prev, 4, 67-70.
10. Kerridge I, Lincz L, Scorgie F, et al (2002) Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol, 118, 477-81.
11. Kracht T, Schrappe M, Strehl S, et al (2004). NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms. Haematologica, 89, 1492-7.
12. Lafuente MJ, Casterad X, Trias M, et al (2000). NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumor. Carcinogenesis, 21, 1813-9.
13. Lanciotti M, Dufour C, Corral L, et al (2004). Genetic polymorphisms of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL rearrangements. Leukemia, 16, [Epub ahead of print].
14. Larson RA, Wang Y, Banerjee M, et al (1999). Prevalence of the inactivating 609C_T polymorphism in the NAD(P)H:quinone oxidoreductase 1 (NOQ1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94, 803-7.
15. Lin P, Wang HJ, Lee HS, et al (1999). The NAD(P)H:quinone oxidoreductase polymorphism and lung cancer in Taiwan. J Toxicol Environ Health, 58, 187-97.
16. Lincz LF, Kerridge I, Scorgie FE, et al (2004). Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Haematologica, 89, 628-9.
17. Loeffler H, Bergmann J, Hochhaus A, et al (2001). Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A. Blood, 98, 3874-5.
18. Longuemaux S, Delomenie C, Gallou C, et al (1999). Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobioticmetabolizing enzymes. Cancer Res, 59, 2903-8.
19. Matsuo K, Suzuki R, Hamajima N, et al (2001). Association between polymorphisms of folate- and methioninemetabolizing enzymes and susceptibility to malignant lymphoma. Blood, 97, 3205-9.
20. Naoe T, Takeyama K, Yokozawa T, et al (2000). Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia / myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res, 6, 4091-5.
21. Nishio K, Tanaka D, Atsuta Y, et al (2004). Genotype announcement in a genetic polymorphism study for health checkup examinees at Nagoya University Hospital. Nagoya J Med Sci, 67, 45-9.
22. Rebbeck TR (1997). Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev, 6, 733-43.
23. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH (1995). Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5, 199-206.
24. Schulz WA, Krummeck A, Rosinger I, et al (1997). Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235-9.
25. Siegel D, McGuiness SM, Winski SL, Ross D (1999). Genotypephenotype relationship in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113-21.
26. Siemankowski LM, Morreale J, Butts BD, Briehl MM (2000). Increased tumor necrosis factor-alpha sensitivity of MCF-7 cells transfected with NAD(P)H:quinone reductase. Cancer Res, 60, 3638-44.
27. Smith MT, Wang Y, Kane E, et al (2001). Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood, 97, 1422-6.
28. Smith MT, Wang Y, Skibola CF, et al (2002). Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood, 100, 4590-3.
29. Wiencke JK, Spitz MR, McMillan A, Kelsey KT (1997). Lung cancer in Mexican-Americans and African-Americans is associated with the wild type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev, 6, 87-92.
30. Xu LL, Wain JC, Miller DP, et al (2001). The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev, 10, 303-9.
31. Yin L, Pu Y, Liu TY, et al (2001). Genetic Polymorphisms of NAD(P)H:quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer, 33, 133-41.